Auditing Clinical Outcomes after Introducing Off-Licence Prescribing of Atypical Antipsychotic Melperone for Patients with Treatment Refractory Schizophrenia by Frank Röhricht, Seema Gadhia, Rinku Alam, Melissa Willis

“…Results. 17 patients with a diagnosis of refractory schizophrenia were identified as suitable for off-license prescribing of Melperone and commenced treatment (13 were previously treated with Clozapine). …”
Get full text

Effects of B Vitamins on Symptoms and Cognitive Functions in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial by Somayeh Agmashe, Gita Sadighi, Narges Radman, Robabeh Mazinani

Subjects: Get full text

Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method by Robert Stewart, Hitesh Shetty, Matthew Broadbent, Angus Roberts, Rashmi Patel, Philip McGuire, Richard D Hayes, Nishamali Jayatilleke, Genevieve Gorrell, Chin-Kuo Chang, Richard Jackson, Nadia Foskett, Caroline Johnston

“…Objectives To identify negative symptoms in the clinical records of a large sample of patients with schizophrenia using natural language processing and assess their relationship with clinical outcomes.Design Observational study using an anonymised electronic health record case register.Setting South London and Maudsley NHS Trust (SLaM), a large provider of inpatient and community mental healthcare in the UK.Participants 7678 patients with schizophrenia receiving care during 2011.Main outcome measures Hospital admission, readmission and duration of admission.Results 10 different negative symptoms were ascertained with precision statistics above 0.80. 41% of patients had 2 or more negative symptoms. …”
Get full text

Stigmatization of people with mental illness – a matter of milieu-specific worldviews? Results from a population-based survey in Germany by Jenny Spahlholz, Eva Baumann, Sven Speerforck, Sven Speerforck, Christian Sander, Christian Sander, Matthias C. Angermeyer, Georg Schomerus, Georg Schomerus

Subjects: Get full text

Reduced γ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk by Junjie Wang, Yingying Tang, Tianhong Zhang, Huiru Cui, Lihua Xu, Botao Zeng, Yu Li, Gaiying Li, Chunbo Li, Hui Liu, Zheng Lu, Jianye Zhang, Jijun Wang

“…Reduced medial prefrontal GABA and Glx levels thus may play an important role in the early stages of schizophrenia.…”
Get full text

Aggression and its correlation with plasma C-reactive protein levels in patients with schizophrenia: A hospital based cross-sectional study by Aru Shikha Singh, Lakshimi Borgohain, Bhupindar Singh

“…Background: The correlation between plasma C-reactive protein (CRP) and aggression in schizophrenia has recently become an area of interest. …”
Get full text

Alternative treatment for schizophrenia with a local wisdom approach in the Tidung tribe community of Tarakan City: a descriptive qualitative study by Darni Darni, Sulidah Sulidah, Ramdya Akbar Tukan, Rts Netisa Martawinarti, Siti Khadijah, Putri Irwanti Sari

Subjects: Get full text

Personalised transcranial magnetic stimulation for treatment-resistant depression, depression with comorbid anxiety and negative symptoms of schizophrenia: a narrative review by Xiao Wei Tan, Hasvinjit Kaur Gulwant Singh, Jovi Zheng Jie Koh, Rachel Si Yun Tan, Phern Chern Tor

“…Recent retrospective brain circuit-based analyses using lesion network mapping have suggested that a left dorsal lateral prefrontal cortex target has a higher efficacy for alleviating depression symptoms, a dorsomedial prefrontal cortex target is more effective for anxiety symptoms, and a rostromedial prefrontal cortex target is effective for schizophrenia-associated psychiatric symptoms. Nonetheless, symptom-specific brain circuit targeting has not been tested prospectively. …”
Get full text

Machine learning-based prediction of antipsychotic efficacy from brain gray matter structure in drug-naive first-episode schizophrenia by Xiaodong Guo, Enpeng Zhou, Xianghe Wang, Bingjie Huang, Tianqi Gao, Chengcheng Pu, Xin Yu

“…Schizophrenia…”
Get full text

Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis by Lucas Hassib, Alexandre Kanashiro, João Francisco Cordeiro Pedrazzi, Bárbara Ferreira Vercesi, Sayuri Higa, Íris Arruda, Yago Soares, Adriana de Jesus de Souza, Alceu Afonso Jordão, Francisco Silveira Guimarães, Frederico Rogério Ferreira

Subjects: Get full text

Sex differences in the peripheral levels of cytokines during 12-month antipsychotic treatment in a drug-naïve schizophrenia spectrum cohort by I. Ratke, A. Torsvik, C.A. Bartz-Johannessen, F. Fathian, I. Joa, S.M. Klæbo Reitan, E.M. Løberg, M. Rettenbacher, S. Skrede, V.M. Steen, E. Johnsen, R.A. Kroken

“…Background: There are substantial sex differences in schizophrenia. However, research addressing sex differences regarding the antipsychotic effect on the immune system is lacking. …”
Get full text

Discrepancies between Self- and Clinical Staff Members’ Perception of Cognitive Functioning among Patients with Schizophrenia Undergoing Long-Term Hospitalization by Fumiko Kaneko, Hitoshi Okamura

“…In Japan, long-term hospitalization of patients with schizophrenia is still prevalent, even though the focus of psychiatric care is shifting from hospitals to the community. …”
Get full text

The burden of depression, anxiety and schizophrenia among the older population in ageing and aged countries: an analysis of the Global Burden of Disease Study 2019 by Wu Hong, Ying Cheng, Yu Fang, Jinxin Zheng, Shiyang Guan, Meiti Wang

“…Background Depression, anxiety and schizophrenia among older persons have become global public health challenges. …”
Get full text

Patient-reported outcome measures to assess mental and physical health status, functionality, and quality of life in patients with major depression or schizophrenia by Luis San, Belen Arranz, Carlota Romans, Berta García, Marta Coromina, Sonia Ortiz, Miriam Vilaplana, Víctor Soto, Ruth Villaescusa, Joan Alvaros

Subjects: Get full text

A Case of Schizophrenia in a Young Male Adult with no History of Substance Abuse: Impact of Clinical Pharmacists’ Interventions on Patient Outcome by Mercy N. A. Opare-Addo, Josephine Mensah, Grace Owusu Aboagye

“…Schizophrenia is a chronic and severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behaviour. …”
Get full text

Efficacy of identifying Treatment-Resistant and non-Treatment-Resistant Schizophrenia using niacin skin flushing response combined with clinical feature by Jizhi Wang, Jinfeng Wang, Siyuan Wang, Yu Gu, Kai Liang, Yingxu Li, Zheng Zhang, Yan Li, Xiaoping Wang, Huijuan Guo, Jiansong Zhou

“…Schizophrenia…”
Get full text

Enhanced computerized cognitive remediation therapy improved cognitive function, negative symptoms, and GDNF in male long-term inpatients with schizophrenia by Peiyun Zhang, Lingyun Chen, Qianqian Qin, Chao Liu, Haijiao Zhu, Wenqing Hu, Wenqing Hu, Xinyu He, Kaihong Tang, Qi Yan, Hongmei Shen, Hongmei Shen

Subjects: “…schizophrenia…”
Get full text

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies by Cassandra Snipes, Cornelia Dorner‑Ciossek, Brendan D Hare, Olya Besedina, Tim Campellone, Mariya Petrova, Shaheen E Lakhan, Abhishek Pratap

“…ObjectiveThis study aimed to investigate the establishment and maintenance of a DWA between a beta version of CT-155/BI 3972080 (CT-155 beta) and adults with ENS of schizophrenia. MethodsTwo multicenter, exploratory, single-arm studies (study 1: CT-155-C-001 and study 2: CT-155-C-002) enrolled adults with schizophrenia and ENS receiving stable antipsychotic medication (≥12 weeks). …”
Get full text

Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy by Vivekananda Rachamallu, Ayman Haq, Michael M. Song, Manish Aligeti

“…Clozapine is an atypical antipsychotic used in the treatment of refractory schizophrenia. It has a well-known side effect profile, including agranulocytosis, decreased seizure threshold, and tardive dyskinesia. …”
Get full text

Basic self-disorders may play a role in the development of depression in schizophrenia: a seven-year follow-up study by Elisabeth Haug, Merete Glenne Øie, Merete Glenne Øie, Ingrid Hartveit Svendsen, Ingrid Hartveit Svendsen, Paul Møller, Barnaby Nelson, Barnaby Nelson, Ingrid Melle, Ingrid Melle

Subjects: “…schizophrenia…”
Get full text